News & Events about Abeona Therapeutics Inc.
Globe Newswire
8 months ago
Disposition of MPS programs to reduce operating expenses andextend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL topline data expected in 3Q 2022 NEW YORK and CLEVELAND, May 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-...
Globe Newswire
9 months ago
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on AAV204, a novel adeno-associated virus (AAV) capsid from Abeonas in-licensed AIM capsid library, will be ...
Globe Newswire
9 months ago
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,000,006 shares of Series...
Globe Newswire
10 months ago
NEW YORK and CLEVELAND, March 28, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics, will participate in a panel discussion titled, Cell ...